Prescriber's Corner
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma
Gwen Hua,(1) PharmD, Daniel Carlson,(2) DO, and Jacqueline R. Starr,(1) PharmD, BCOP
From (1)Geisinger Enterprise Pharmacy, Danville, Pennsylvania; (2)Geisinger Cancer Institute, Danville, Pennsylvania
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Gwen Hua, PharmD,
100 N Academy Ave, Danville, PA 17822
E-mail: ghua@geisinger.edu
J Adv Pract Oncol 2022;13(7):717–723 |
https://doi.org/10.6004/jadpro.2022.13.7.8 |
© 2022 Harborside™
ABSTRACT
Uveal melanoma is the most common intraocular cancer in adults. Metastatic uveal melanoma has a poor prognosis. Tebentafusp-tebn is the first drug in the new immune mobilizing monoclonal T-cell receptors against cancer (ImmTAC) class of T cell–directed therapy. Tebentafusp-tebn has been shown in a randomized phase III clinical trial to lead to improved overall survival and progression-free survival when compared with single-agent pembrolizumab, ipilimumab, or dacarbazine in previously untreated human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma patients. Tebentafusp-tebn is now approved by the US Food and Drug Administration in HLA-A*02:01-positive uveal melanoma patients as first-line therapy in the metastatic setting.
For access to the full length article, please
sign in.
